Strategic CDO — Pharma & Biotech transformation & growth (Singapore)

Position overview

Gladwin International Leadership Advisors is representing a confidential organisation in Pharmaceuticals & Biotechnology on a senior CDO leadership mandate anchored in Singapore. The remit explicitly spans Africa, China, Continental Europe.

This is a strategic transformation mandate at CXO level — equal parts operating leadership, change orchestration, and investor / board narrative ownership.

Expect a mandate where credibility is earned in rooms with customers and regulators, not only in headquarters workshops.

Context you will inherit

• Market & sector: Market access and pricing — as governments globally drive price controls, finding leaders who can manage market access, pricing strategy, and government affairs with sophistication
• Geographic spine: Primary hub Singapore with explicit corridor responsibility across Africa, China, Continental Europe.
• Organisation stage: Growth agenda collides with legacy cost base; productivity and automation are board-level topics, not staff functions.
• Stakeholders: Owners may include PE operating partners, a promoter family office, or public-market investors — each with different tempo and KPIs.
• Secondary lens: Biosimilars and specialty pharma commercialisation — moving from commoditised generics to branded specialty requires entirely new commercial leadership capabilities

The mandate (12–24 month arc)

1. Executive dashboards: Replace vanity metrics with a tight set of KPIs the CEO and CFO trust.
2. Customer data: Unify identity and consent where fragmentation hurts personalisation or compliance.
3. Operational analytics: Use data to improve unit economics in operations — yield, utilisation, leakage.
4. Partnership with IT: Clarify split between CDO-owned capabilities and CIO-owned platforms.
5. Regulatory reporting: Where applicable, reduce manual reconciliation through better lineage and controls.
6. Talent: Hire leaders who can translate statistical insight into executive decisions — not only build models.

Responsibilities (representative)

• Reduce regulatory and audit pain on data lineage, privacy, and retention.
• Monetise or operationalise data assets where ethically and legally sound.
• Hire and retain data science and engineering talent in competitive markets.
• Align metrics definitions across finance, operations, and commercial teams.
• Lead MDM and reference data programmes where fragmentation blocks decisions.

Leadership profile

• Judgment: High signal-to-noise under pressure; ethical clarity; willingness to halt initiatives that break risk appetite.
• Trusted metrics: Examples where data changed capital or operating decisions in Pharmaceuticals & Biotechnology.
• Education: Strong undergraduate grounding; MBA / advanced degree / professional qualification common at this level.
• Communication: Executive presence in English; additional languages valued where market-relevant.
• Geographic muscle: Comfort operating from Singapore with regular engagement across Africa, China.

Team & culture

Expect some fatigue from prior change programmes. Your success depends on simpler priorities, fewer initiatives, and leaders who model accountability. Culture is how decisions get made when spreadsheets disagree — you set that tone.

Success measures (examples)

• Value creation: EBITDA / cash trajectory vs. owner or board case — especially under stress scenarios.
• Execution: On-time delivery of named transformation milestones; reduction in repeat incidents or audit findings.
• Leadership: External hires and internal promotions that stick; reduction in key-person concentration.
• Innovation: Launched offers or capabilities that move the needle on differentiation, not pilots that stall.

First 90 days (orientation arc)

• Days 1–30: Map cash, covenant, and customer concentration risks before announcing initiatives.
• Days 30–60: Align owners and board on a 12-month value story — financial and non-financial.
• Days 60–90: Launch two quick operational fixes that build credibility with frontline managers.
• Deep-dive on talent — who is load-bearing, who is blocking, where external hire is mandatory.
• Socialise a simple KPI tree so every function sees how their metrics roll up.

Stakeholder map (illustrative)

• Internal: Executive committee, functional peers, shared services leads, and programme PMOs.
• External: Key suppliers, technology partners, and joint-venture boards where applicable.
• Board / owners: Expect deep dives on risk, liquidity, talent, and transformation — slides light, substance heavy.

Travel & mobility

Travel weighted to priority markets and quarterly global or regional forums; flexibility for crisis windows.

Compensation

Package aligned to CDO benchmarks in Pharmaceuticals & Biotechnology — typically fixed, variable, benefits, and mobility where applicable. Structure detailed at shortlist.

Application status

This mandate is no longer accepting new applications. The search progressed through Q4 2025 and closed for submissions in February 2026. We retain this posting for transparency on the type of leadership work we carry in Pharmaceuticals & Biotechnology and Singapore. For similar active mandates, browse open roles or submit a general profile through executive search inquiry.

Reference: pharmaceuticals-biotech · CDO · Singapore · Gladwin International Leadership Advisors